Trial Profile
A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
- 20 Sep 2009 Results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology (ECCO/ESMO 2009).
- 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.